Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Immunoglobulin Light-chain Amyloidosis × belantamab mafodotin × 30 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 4 Plasmablastic Lymphoma 1 Immunoglobulin Light-chain Amyloidosis 1 Amyloidosis 1

Interventions

Dexamethasone 7 Bortezomib 5 Cyclophosphamide 4 venetoclax 2 Clinical Protocols 2 pomalidomide 1 ixazomib 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 daratumumab 1 belantamab mafodotin 1 auricularum 1 X-Rays 1 Specimen Handling 1 Pharmaceutical Preparations 1 Phantoms, Imaging 1 Magnetic Resonance Spectroscopy 1 Calcium Dobesilate 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡